Poseida Therapeutics Balance Sheet Health
Financial Health criteria checks 5/6
Poseida Therapeutics has a total shareholder equity of $87.2M and total debt of $58.9M, which brings its debt-to-equity ratio to 67.5%. Its total assets and total liabilities are $293.6M and $206.4M respectively.
Key information
67.5%
Debt to equity ratio
US$58.91m
Debt
| Interest coverage ratio | n/a |
| Cash | US$230.85m |
| Equity | US$87.21m |
| Total liabilities | US$206.37m |
| Total assets | US$293.58m |
Recent financial health updates
Poseida Therapeutics (NASDAQ:PSTX) Has Debt But No Earnings; Should You Worry?
May 21
Poseida Therapeutics (NASDAQ:PSTX) Has Debt But No Earnings; Should You Worry?
Jan 24Recent updates
Investors Don't See Light At End Of Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Tunnel And Push Stock Down 30%
Oct 19Poseida: Interim P-BCMA-ALLO1 Data Bodes Well For Phase 1B Advancement
Sep 30Poseida Therapeutics: An Underappreciated Company Continuing To Shape Up Well In 2024
Sep 09Lacklustre Performance Is Driving Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) 29% Price Drop
Aug 28Poseida Therapeutics (NASDAQ:PSTX) Has Debt But No Earnings; Should You Worry?
May 21Investors Don't See Light At End Of Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Tunnel And Push Stock Down 27%
Apr 09Poseida: April 2024 Data Could Shed Light On Differentiated CAR-T Advancement
Mar 17Poseida Therapeutics (NASDAQ:PSTX) Has Debt But No Earnings; Should You Worry?
Jan 24Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Share Price Boosted 43% But Its Business Prospects Need A Lift Too
Dec 18New Forecasts: Here's What Analysts Think The Future Holds For Poseida Therapeutics, Inc. (NASDAQ:PSTX)
Aug 13Little Excitement Around Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Revenues As Shares Take 44% Pounding
Apr 17Poseida Therapeutics: Collaboration Agreement With Roche Helps Validate Genetic Engineering Tech
Sep 04Poseida Therapeutics GAAP EPS of -$0.69 beats by $0.08, revenue of $2.7M beats by $1.77M
Aug 11Poseida jumps 56% as Roche eyes CAR-T drugs in deal worth up to $6B
Aug 03Earnings Release: Here's Why Analysts Cut Their Poseida Therapeutics, Inc. (NASDAQ:PSTX) Price Target To US$16.25
May 15Poseida Therapeutics: Genome Engineering For Safer Cell Therapies
Oct 30What Type Of Shareholders Make Up Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Share Registry?
Mar 19Did Poseida Therapeutics, Inc. (NASDAQ:PSTX) Insiders Buy Up More Shares?
Jan 25Poseida Therapeutics (PSTX) Presents At 62nd Virtual Annual Meeting of ASH - Slideshow
Dec 09FDA lifts clinical hold on Poseida's prostate cancer cell therapy study
Nov 02Financial Position Analysis
Short Term Liabilities: PSTX's short term assets ($250.7M) exceed its short term liabilities ($78.3M).
Long Term Liabilities: PSTX's short term assets ($250.7M) exceed its long term liabilities ($128.1M).
Debt to Equity History and Analysis
Debt Level: PSTX has more cash than its total debt.
Reducing Debt: PSTX's debt to equity ratio has increased from 52.1% to 67.5% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: PSTX has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: PSTX has sufficient cash runway for 1.7 years if free cash flow continues to grow at historical rates of 10% each year.